2024-07-05 00:05:42 ET
Summary
- Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer.
- Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine.
- CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Celcuity: Flying A Phase 3 Trial Right Under Your Nose